Drug Name: | Dabigatran etexilate |
---|
Drug Class: | Direct oral anticoagulant (DOAC) |
---|
Mechanism of Action: | Inhibits thrombin, preventing the formation of blood clots |
---|
Use: | - Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation
- Treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE)
- Prevention of recurrent DVT and PE
|
---|
Side Effects: | - Bleeding (including gastrointestinal and intracranial bleeding)
- Dyspepsia (indigestion)
- Gastritis
- Nausea
- Abdominal pain
- Headache
|
---|
Contraindications: | - Active bleeding
- Mechanical prosthetic heart valve
- Severe renal impairment (CrCl < 30 mL/min)
|
---|
Specialty: | - Cardiology
- Hematology
- Internal Medicine
|
---|